The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome.

Tauber M, Boulanouar K, Diene G, Çabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, Cessans C, Viaux-Sauvelon S and 11 more

Show all authors

Bascoul C, Guedeney A, Delhanty P, Geenen V, Martens H, Muscatelli F, Cohen D, Consoli A, Payoux P, Arnaud C, Salles JP

Pediatrics1 Feb 2017Cited by 126 (Europe PMC)

PMID28100688DOI10.1542/peds.2016-2976PepBankPUB-28100688

Publisher page PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialSafety outcome
In infants with Prader-Willi syndrome, no adverse events were reported with a 7-day course of intranasal oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, no side effects were reported during a short course of nasal oxytocin.
Peptide
Oxytocin
Outcome
No significant changeAdverse events
Study
n = 18
Outcome group
Adverse events · Whole body
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
No adverse events were reported.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068801
02HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, no dose effect was observed across the three oxytocin dosing schedules.
In plain wordsIn infants with Prader-Willi syndrome, the three oxytocin dosing schedules showed no difference in effect.
Peptide
Oxytocin
Outcome
No significant changeDose effect on outcomes
Study
n = 18
Outcome group
Appetite and food intake · Whole body
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
No dose effect was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068802
03HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, sucking was abnormal in all infants at baseline and normalized in 88% after oxytocin treatment.
In plain wordsIn infants with Prader-Willi syndrome, sucking was abnormal at baseline and became normal in most infants after nasal oxytocin.
Peptide
Oxytocin
Outcome
Not applicableNormalization of sucking on the Neonatal Oral-Motor Scale
Study
n = 18
Outcome group
Appetite and food intake · Nervous system and cognition
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Measurements
Proportion with normalized sucking
88%
after treatment
Source sentences
Summary
Sucking assessed by the Neonatal Oral-Motor Scale was abnormal in all infants at baseline and normalized in 88% after treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068803
04HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, Neonatal Oral-Motor Scale scores decreased significantly from 16 to 9 after oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, sucking scores changed from 16 to 9 after nasal oxytocin treatment.
Peptide
Oxytocin
Outcome
DecreaseNeonatal Oral-Motor Scale score
Study
n = 18
Outcome group
Appetite and food intake · Nervous system and cognition
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Measurements
Neonatal Oral-Motor Scale score
16 score
baseline
Neonatal Oral-Motor Scale score
9 score
after treatment
Source sentences
Summary
The scores of Neonatal Oral-Motor Scale and videofluoroscopy of swallowing significantly decreased from 16 to 9 (P < .001)
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068804
05HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, videofluoroscopy of swallowing scores decreased significantly from 18 to 12.5 after oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, swallowing scores changed from 18 to 12.5 after nasal oxytocin treatment.
Peptide
Oxytocin
Outcome
DecreaseVideofluoroscopy of swallowing score
Study
n = 18
Outcome group
Appetite and food intake · Nervous system and cognition
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Measurements
Videofluoroscopy of swallowing score
18 score
baseline
Videofluoroscopy of swallowing score
12.5 score
after treatment
Source sentences
Summary
The scores of Neonatal Oral-Motor Scale and videofluoroscopy of swallowing significantly decreased from 16 to 9 (P < .001) and from 18 to 12.5 (P < .001), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068805
06HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, Clinical Global Impression scale scores improved significantly after oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, clinician-rated overall scores improved after nasal oxytocin.
Peptide
Oxytocin
Outcome
Not applicableClinical Global Impression scale scores
Study
n = 18
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
Significant improvements in Clinical Global Impression scale scores, social withdrawal behavior, and mother-infant interactions were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068806
07HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, social withdrawal behavior improved significantly after oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, social withdrawal behavior improved after nasal oxytocin.
Peptide
Oxytocin
Outcome
Not applicableSocial withdrawal behavior
Study
n = 18
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
Significant improvements in Clinical Global Impression scale scores, social withdrawal behavior, and mother-infant interactions were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068807
08HumanNon-randomized trialEfficacy outcome
In infants with Prader-Willi syndrome, mother-infant interactions improved significantly after oxytocin.
In plain wordsIn infants with Prader-Willi syndrome, mother-infant interactions improved after nasal oxytocin.
Peptide
Oxytocin
Outcome
Not applicableMother-infant interactions
Study
n = 18
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
Significant improvements in Clinical Global Impression scale scores, social withdrawal behavior, and mother-infant interactions were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068808
09HumanNon-randomized trialMechanism
In infants with Prader-Willi syndrome, oxytocin significantly increased acylated ghrelin.
In plain wordsIn infants with Prader-Willi syndrome, nasal oxytocin raised levels of acylated ghrelin.
Peptide
Oxytocin
Outcome
IncreaseCirculating acylated ghrelin
Study
n = 18
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
We documented a significant increase in acylated ghrelin
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068809
10HumanNon-randomized trialMechanism
In infants with Prader-Willi syndrome, oxytocin significantly increased connectivity of the right superior orbitofrontal network, which correlated with changes in sucking and behavior.
In plain wordsIn infants with Prader-Willi syndrome, nasal oxytocin increased brain connectivity in one network, which tracked changes in sucking and behavior.
Peptide
Oxytocin
Outcome
IncreaseConnectivity of the right superior orbitofrontal network
Study
n = 18
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
4 IU every other day, daily, or twice daily · intranasal · 7 daysAs given in this study (human).
Source sentences
Summary
connectivity of the right superior orbitofrontal network that correlated with changes in sucking and behavior.
1 context sentence(design, population, supporting numbers)
Summary · context
We enrolled 18 infants with PWS under 6 months old (6 infants in each step) who received 4 IU of OXT either every other day, daily, or twice daily.
Report a problemFND-2810068810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2Results postedNCT02205034

Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants

University Hospital, Toulousen = 18May 2013 to Jul 2014

Prader Willi Syndrome

Trial page ClinicalTrials.govUpdated 21 Feb 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.